We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+7.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$128M
AUM Growth
+$12.3M
Cap. Flow
+$10.9M
Cap. Flow %
8.47%
Top 10 Hldgs %
63.26%
Holding
34
New
7
Increased
9
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
HROW icon
Harrow
HROW
+$3.7M
2
PRTA icon
Prothena Corp
PRTA
+$3.05M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.03M
4
GERN icon
Geron
GERN
+$2.02M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.01M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$2.55M
2
MZOR
Mazor Robotics Ltd.
MZOR
+$2.11M
3
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$1.76M
4
PCYC
PHARMACYCLICS INC
PCYC
+$1.71M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.66%
2 Miscellaneous 13.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
$20.9M 16.25%
755,000
-35,000
-4% -$850K
PCYC
2
DELISTED
PHARMACYCLICS INC
PCYC
$9.98M 7.78%
85,000
-15,000
-15% -$1.71M
TVTX icon
3
Travere Therapeutics
TVTX
$6.36B
$9.02M 7.03%
1,000,000
-216,400
-18% -$2.55M
ARIA
4
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$8.1M 6.31%
1,500,000
-160,000
-10% -$934K
AGIO icon
5
Agios Pharmaceuticals
AGIO
$2.05B
$6.96M 5.43%
113,500
-1,500
-1% -$64.7K
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$6.21M 4.84%
140,000
+10,000
+8% +$418K
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$5.53M 4.31%
504,800
– –
GNMK
8
DELISTED
GenMark Diagnostics, Inc
GNMK
$4.93M 3.85%
550,000
+50,000
+10% +$538K
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.59B
$4.81M 3.75%
85,000
+40,000
+89% +$2.01M
INSY
10
DELISTED
Insys Therapeutics, Inc.
INSY
$4.75M 3.7%
245,000
+73,400
+43% +$1.15M
NSPR icon
11
InspireMD
NSPR
$41.6M
– –
0
– –
CDXS icon
12
Codexis
CDXS
$182M
$3.94M 3.07%
1,690,000
+870,000
+106% +$1.87M
BIND
13
DELISTED
BIND THERAPEUTICS INC
BIND
$3.87M 3.01%
450,000
-42,000
-9% -$414K
HROW icon
14
Harrow
HROW
$1.44B
$3.73M 2.91%
+502,500
New +$3.7M
PRTA icon
15
Prothena Corp
PRTA
$467M
$3.48M 2.71%
157,000
+143,896
+1,098% +$3.05M
TTPH
16
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.39M 2.64%
8,485
– –
CPRX
17
DELISTED
Catalyst Pharmaceutical
CPRX
$3.24M 2.52%
975,000
-403,584
-29% -$1.05M
CSII
18
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.95M 2.3%
125,000
-10,000
-7% -$284K
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$31.7B
$2.27M 1.77%
29,100
+21,900
+304% +$1.41M
CELGZ
20
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$2.24M 1.74%
660,000
– –
AEGR
21
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.92M 1.5%
+57,500
New +$1.78M
AXDX
22
DELISTED
Accelerate Diagnostics
AXDX
$1.92M 1.49%
+8,920
New +$1.73M
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.71M 1.33%
+134,500
New +$2.03M
LAB icon
24
Standard BioTools
LAB
$256M
$1.64M 1.28%
+67,000
New +$1.88M
GERN icon
25
Geron
GERN
$983M
$1.64M 1.28%
+820,000
New +$2.02M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2014 Portfolio in Review

As of Q3 2014, Opaleye Management held 34 positions worth $128M, up 11% from $116M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opaleye Management deployed $10.9M of net new capital in Q3 2014, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was Harrow: 502,500 shares worth $3.73M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.55M trimmed.

  • Opaleye Management's largest Q3 2014 buy was Harrow: 502,500 shares worth $3.73M.
  • Opaleye Management added most to Prothena Corp in Q3 2014, an estimated $3.05M increase.
  • Opaleye Management's biggest Q3 2014 reduction was Travere Therapeutics, cutting an estimated $2.55M.
  • Opaleye Management fully exited Mazor Robotics Ltd. in Q3 2014, selling an estimated $2.11M.
  • Opaleye Management's ten largest holdings make up 63% of its $128M portfolio in Q3 2014.
  • Opaleye Management opened 7 new positions and closed 4 in Q3 2014.
  • Opaleye Management's portfolio value rose 11% quarter-over-quarter to $128M.

Based on Opaleye Management's 13F filing for Q3 2014, filed 14 Nov 2014.